ABSTRACT
BACKGROUND AND OBJECTIVE: We investigated atorvastatin effectiveness and tolerance in HIV patients with hypercholesterolemia related to antiretroviral treatment. PATIENTS AND METHOD: Prospective study that included HIV+ patients under antiretroviral treatment who displayed secondary dyslipemia and medical treatment criteria (according to NCEP-III). These patients were given 10 mg/day atorvastatin and hygienic-dietetic measures. If the therapeutic objectives were not achieved, the dose of atorvastatin was increased to 20 mg/day. Patients were followed up for 6 months. RESULTS: 32 patients were included. In 5 cases it was necessary to increase the dose from 10 mg atorvastatin to 20 mg. The therapeutic objective was obtained in 62% cases, with a good clinical tolerance. Only one adverse effect was noticed, which forced the removal of the drug. CONCLUSION: In our study atorvastatin was effective for the treatment of dyslipemia in HIV patients, and it was safe and well tolerated.
Subject(s)
Antiretroviral Therapy, Highly Active/adverse effects , Heptanoic Acids/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/chemically induced , Hypercholesterolemia/drug therapy , Pyrroles/therapeutic use , Adult , Aged , Atorvastatin , Female , HIV Infections/drug therapy , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Fundamento y objetivo: Conocer la utilidad clínica del tratamiento hipolipemiante con atorvastatina en pacientes infectados por el virus de la inmunodeficiencia humana (VIH) con hipercolesterolemia asociada al tratamiento antirretroviral, así como su tolerabilidad. Pacientes y método: Estudio observacional, prospectivo y no controlado que incluye a pacientes infectados por el VIH en tratamiento antirretroviral que presentan dislipemia secundaria con criterios de tratamiento médico según el National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). La intervención terapéutica realizada fue atorvastatina a dosis de 10 mg/día y medidas higiénico-dietéticas. Si a los 3 meses de tratamiento no se alcanzaba los objetivos terapéuticos, se aumentaba la dosis de atorvastatina a 20 mg/día. Se realizó un seguimiento clínico y analítico durante 6 meses. Resultados: Se incluyó a 32 pacientes. En 5 casos se precisó aumentar la dosis de 10 a 20 mg de atorvastatina al día. En un 62% de los casos se consiguió el objetivo terapéutico con buena tolerancia clínica. Se observó un efecto adverso que obligó a retirar el fármaco. Conclusión: En este estudio, la atorvastatina ha resultado ser eficaz y bien tolerada para el tratamiento de la dislipemia en la población infectada por el VIH+
Background and objective: We investigated atorvastatin effectiveness and tolerance in HIV patients with hypercholesterolemia related to antiretroviral treatment. Patients and method: Prospective study that included HIV+ patients under antiretroviral treatment who displayed secondary dyslipemia and medical treatment criteria (according to NCEP-III). These patients were given 10 mg/day atorvastatin and hygienic-dietetic measures. If the therapeutic objectives were not achieved, the dose of atorvastatin was increased to 20 mg/day. Patients were followed up for 6 months. Results: 32 patients were included. In 5 cases it was necessary to increase the dose from 10 mg atorvastatin to 20 mg. The therapeutic objective was obtained in 62% cases, with a good clinical tolerance. Only one adverse effect was noticed, which forced the removal of the drug. Conclusion: In our study atorvastatin was effective for the treatment of dyslipemia in HIV patients, and it was safe and well tolerated
